Evidence map›Paper›PMID 42139373›Full record

ArticlePloS one2026

Equity premium forecasting with reliability-screened forward-looking signals.

Jeonggyu Huh, Jaegi Jeon, Seungwon Jeong

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jeonggyu HuhDepartment of Mathematics, Sungkyunkwan University, Suwon, Republic of Korea.
Jaegi JeonGraduate School of Data Science, Chonnam National University, Gwangju, Republic of Korea.
Seungwon JeongGlobal-Learning & Academic research institution for Master's· PhD students, Chonnam National University, Gwangju, Republic of Korea.ORCID https://orcid.org/0009-0000-6873-9969

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Forecasting the equity risk premium is challenging because predictive relationships are unstable out of sample. We propose a two-stage framework that generates forward-looking signals from standard macro-financial predictors and admits them only when they satisfy predictor-level reliability criteria. In Stage 1, each predictor is forecast one step ahead to obtain an expected movement and an uncertainty proxy. In Stage 2, lagged predictors are augmented with the admitted signals and mapped into next-period excess returns using random forests, optionally combined with SHAP-guided screening and dimension reduction. Using monthly U.S. data from 1952 to 2024, we evaluate both benchmark-relative out-of-sample accuracy and the economic value of forecasts in a constrained mean-variance allocation. Selective admission improves out-of-sample accuracy and, in selected specifications, yields economically meaningful gains in risk-adjusted performance and drawdown control. Tail-conditional diagnostics show that these gains are concentrated disproportionately in downside market states, helping explain when statistical improvements translate into economic value. The main qualitative patterns remain robust across alternative learners, across the S&P 500 and the CRSP value-weighted market index, and under net of transaction cost evaluation and alternative portfolio volatility checks. Taken together, the findings suggest that forward-looking predictor information is most useful when admitted selectively on the basis of predictor-level reliability, with its practical value lying less in universal forecast improvements than in more robust and downside-sensitive equity premium forecasting.

Indexed as

Models, EconomicForecastingHumansPrediction AlgorithmsReproducibility of ResultsUnited States

Identifiers

PMID42139373
PMCPMC13178993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.